Chlamydia Testing: Window Periods, Accuracy, and What National Data Show

Chlamydia is a common sexually transmitted infection caused by the bacterium Chlamydia trachomatis. It can infect people of any gender and is spread through vaginal, anal, or oral sex with an infected partner. You cannot tell from looking at someone whether they carry it, and many people who have it feel completely well.

According to CDC, chlamydia is the most commonly reported bacterial infection in the United States. Rates are highest among adolescents and young adults, but screening recommendations extend well beyond that age range depending on your situation.

CDC notes that chlamydial infections are usually asymptomatic in both men and women. When symptoms do appear, they may include unusual discharge, burning during urination, or (in women) bleeding between periods or after sex — but symptoms can be mild enough to ignore or may not show up for weeks after exposure.

This is the central reason testing matters. Because infection can be present with no symptoms at all, a test is the only way to know your status. If symptoms are present, a healthcare provider can evaluate what is going on; if you feel fine, testing still answers the question a symptom check cannot.

Chlamydia is most commonly detected with a nucleic acid amplification test (NAAT) run on a urine sample or a vaginal swab. CDC treatment guidance describes NAATs as the most sensitive tests available for these specimens, which is why they are the recommended method for chlamydia detection.

Timing matters as much as the test itself: a test taken too early can miss a recent infection, even with an accurate method. CDC does not publish one fixed window period number for chlamydia NAATs; practical guidance commonly used in clinical care is to test roughly 1 to 2 weeks after a possible exposure, and CDC post-exposure guidance supports repeating an earlier negative NAAT at that interval when a recent exposure is possible. If a result comes back negative very soon after a possible exposure, planning a follow-up test is a reasonable step to discuss with a clinician.

A negative result only reflects the moment it was collected. If exposures have continued since the test, or a new partner is involved, screening on a regular schedule — for example the annual screening CDC recommends for sexually active women under 25 and others at increased risk — keeps the answer current.

Because chlamydia is usually silent, an infection can persist without anyone noticing. CDC documents that untreated chlamydial infection can lead to pelvic inflammatory disease (PID), ectopic pregnancy, and infertility in women, and some people already have subclinical upper genital tract infection when it is found on a screening test. Finding the infection early is how these outcomes get interrupted.

CDC also notes that chlamydia screening programs have been shown to reduce rates of PID among women. Testing is a practical, private step: a lab visit, a urine sample or swab, and a result you can act on.

In its 2023 surveillance report, CDC counted 1,648,568 reported chlamydia cases in the United States — a national rate of 492.2 per 100,000 people and roughly stable compared with 2022. About 55.8 percent of reported cases were among people aged 15 to 24. CDC emphasizes that because infections are usually asymptomatic, case counts are heavily shaped by how much screening happens.

Local rates vary meaningfully. Across the 100 largest US metros, 2023 metro-level surveillance data show a mean chlamydia rate of 620.63 per 100,000, with a standard deviation of 175.82 — meaning many metros sit well above or below that average depending on screening coverage and population mix. Nationally, the overall STI picture has shown some easing: CDC reported total chlamydia, gonorrhea, and syphilis cases down 1.8 percent from 2022 to 2023, with chlamydia essentially flat. Trends like these are encouraging without changing the basic screening advice for individuals.

Lab-based chlamydia testing through an online order is processed at a Labcorp or Quest patient service center, with thousands of locations nationwide. You can order a single chlamydia test or choose a broader STD panel that covers multiple infections in one visit — panels usually make sense if more than one infection is a realistic possibility.

Insurance is optional. Using insurance may mean the claim appears on an explanation of benefits sent to the policyholder; paying out of pocket keeps the visit off insurance paperwork entirely, which is a common reason people choose self-pay. Current pricing for single tests and panels lives on the STDcheck pricing page, and a $10-off coupon flow is available at checkout. No referral or clinic visit is required to order.